AKT1 and colorectal cancer: A multiplex diagnostic panel combining m6A-lncRNA signatures with PTEN promoter methylation and phosphorylated EGFR/AKT detection could predict drug responsiveness and guide targeted therapy selection, as demonstrated in endometrial and colorectal cancer models.[45,46] Second, m6A-modified lncRNAs regulating β-catenin binding may serve as noninvasive biomarkers.